LOCALLY ADVANCED SOLID TUMOR
Clinical trials for LOCALLY ADVANCED SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMOR trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug TNG908 tested in patients with rare gene deletion
Disease control TerminatedThis study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have lost a gene called MTAP. The goal was to see if the drug is safe and can shrink tumors. The study was planned for up to 192 participants but was terminated early, so results a…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC